Evidence map›Paper›PMID 40323723›Full record

ReviewCancer2025

The evolving therapeutic revolution in adult acute lymphoblastic leukemia.

Hagop Kantarjian, Nitin Jain, Mark R Litzow, Selina M Luger, Cristina Papayannidis, Josep-Maria Ribera, Nicholas J Short, Helen T Chifotides, Elias Jabbour

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-1908-3307
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Mark R LitzowDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Selina M LugerAbramson Cancer Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Cristina PapayannidisIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.ORCID https://orcid.org/0000-0001-8705-8333
Josep-Maria RiberaClinical Hematology Department and Stem Cell Transplantation Unit, Catalan Institute of Oncology, Barcelona, Spain.ORCID https://orcid.org/0000-0003-1042-6024
Nicholas J ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-2983-2738
Helen T ChifotidesDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-8044-4960
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-4465-6119

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Charif Souki Cancer Research FundNational Cancer Institute/National Institutes of Health P30 CA016672NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

The past decade has witnessed remarkable advances in deciphering the pathophysiology of acute lymphoblastic leukemia (ALL) and in developing novel targeted therapies. Basic research and genomic mapping have identified new prognostic biomarkers, targets, and ALL subtypes (e.g., Philadelphia-like ALL). The ongoing therapeutic revolution in ALL is driven by the addition to the treatment arsenal of therapies that target the ABL fusions, like the BCR::ABL1 tyrosine kinase inhibitors, as well as novel agents that target CD19 and CD22: the CD22 antibody-drug conjugate inotuzumab ozogamicin, the bispecific CD3/CD19 T-cell engager antibody blinatumomab, and CD19 chimeric antigen receptor T-cell therapies. These combinations have improved the long-term survival rates in B-cell ALL to 70%, and in Philadelphia chromosome-positive ALL to 80%-90%. The desired goals are to achieve cure rates comparable to those in pediatric ALL and to reduce or eliminate the need for prolonged intensive/maintenance chemotherapy and associated toxicities.

Indexed as

Precursor Cell Lymphoblastic Leukemia-LymphomaAdultAntibodies, BispecificAntibodies, Monoclonal, HumanizedAntigens, CD19Fusion Proteins, bcr-ablHumansInotuzumab OzogamicinMolecular Targeted TherapyProtein Kinase InhibitorsSialic Acid Binding Ig-like Lectin 2Antibodies, BispecificAntibodies, Monoclonal, HumanizedAntigens, CD19blinatumomabFusion Proteins, bcr-ablInotuzumab OzogamicinProtein Kinase InhibitorsSialic Acid Binding Ig-like Lectin 2acute lymphoblastic leukemiablinatumomabchemotherapy‐free regimenchimeric antigen receptor (CAR) T‐cell therapyimmunotherapyinotuzumabponatinibtyrosine kinase inhibitor

Identifiers

PMID40323723
PMCPMC12309614

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.